Charles Rudin completed his MD, PhD, medical and oncology training at the University of Chicago, where he joined the department of medicine faculty in 1998. He directed the lung, esophageal and head and neck cancer program at Johns Hopkins University from 2003 to 2013, while also serving as associate cancer center director for clinical research. He joined Memorial Sloan Kettering Cancer Center in 2013 as chief of thoracic oncology, co-director of the Druckenmiller Center for Lung Cancer Research, and the Sylvia Hassenfeld Chair in Lung Cancer Research.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
The work by C.M.R. on SCLC is supported by an NCI grants R35 CA263816 and U24 CA213274.
C.M.R. has consulted about oncology drug development with AbbVie, Amgen, Astra Zeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, Lilly, Merck, and Syros. He serves on the scientific advisory boards of Auron, Bridge Medicines, DISCO, Earli, and Harpoon Therapeutics.
About this article
Cite this article
Rudin, C.M. Breathing room – focusing on the ‘other’ lung cancer. Nat Cancer 4, 1212–1213 (2023). https://doi.org/10.1038/s43018-023-00569-0